[go: up one dir, main page]

MXPA06015037A - Composiciones que contienen aequorina y metodos para usar las mismas. - Google Patents

Composiciones que contienen aequorina y metodos para usar las mismas.

Info

Publication number
MXPA06015037A
MXPA06015037A MXPA06015037A MXPA06015037A MXPA06015037A MX PA06015037 A MXPA06015037 A MX PA06015037A MX PA06015037 A MXPA06015037 A MX PA06015037A MX PA06015037 A MXPA06015037 A MX PA06015037A MX PA06015037 A MXPA06015037 A MX PA06015037A
Authority
MX
Mexico
Prior art keywords
methods
aequorin
same
containing compositions
oralleviating
Prior art date
Application number
MXPA06015037A
Other languages
English (en)
Inventor
Mark Y Underwood
Original Assignee
Quincy Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quincy Bioscience Llc filed Critical Quincy Bioscience Llc
Publication of MXPA06015037A publication Critical patent/MXPA06015037A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)

Abstract

Se proporcionan por la presente invencion composiciones que contienen aequorina y metodos para su uso en la prevencion y/o alivio de los sintomas y trastornos relacionados con el desequilibrio de calcio.
MXPA06015037A 2004-06-21 2005-06-21 Composiciones que contienen aequorina y metodos para usar las mismas. MXPA06015037A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/872,795 US20060229243A1 (en) 2004-06-21 2004-06-21 Aequorin-containing compositions and methods of using same
PCT/US2005/021770 WO2006010004A2 (en) 2004-06-21 2005-06-21 Aequorin-containing compositions and methods of using same

Publications (1)

Publication Number Publication Date
MXPA06015037A true MXPA06015037A (es) 2007-07-11

Family

ID=35785748

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06015037A MXPA06015037A (es) 2004-06-21 2005-06-21 Composiciones que contienen aequorina y metodos para usar las mismas.

Country Status (20)

Country Link
US (3) US20060229243A1 (es)
EP (2) EP1768691B1 (es)
JP (1) JP4971150B2 (es)
KR (1) KR101213555B1 (es)
CN (1) CN1997383B (es)
AU (1) AU2005265266B2 (es)
BR (1) BRPI0512392B1 (es)
CA (1) CA2571542C (es)
CY (1) CY1114307T1 (es)
DK (1) DK1768691T3 (es)
ES (1) ES2422173T3 (es)
IL (1) IL180195A (es)
MX (1) MXPA06015037A (es)
NZ (1) NZ552274A (es)
PL (1) PL1768691T3 (es)
PT (1) PT1768691E (es)
SG (1) SG153848A1 (es)
SI (1) SI1768691T1 (es)
WO (1) WO2006010004A2 (es)
ZA (1) ZA200610688B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060229243A1 (en) * 2004-06-21 2006-10-12 Quincy Resource Group, Inc. Aequorin-containing compositions and methods of using same
GB0625678D0 (en) * 2006-12-21 2007-01-31 Lux Biotechnology Ltd Composition and method for detection of demineralisation
SI2262525T1 (sl) 2008-03-11 2013-03-29 Quincy Bioscience, Llc Apoaekuorin vsebujoči sestavki in postopki njihove uporabe
JP2010143860A (ja) * 2008-12-19 2010-07-01 Chisso Corp タンパク質の安定化剤
US20110130336A1 (en) * 2009-10-16 2011-06-02 Quincy Bioscience, Llc Method of treating ischemic injury using apoaequorin
BR112013015605A2 (pt) * 2010-12-24 2016-10-11 Otsuka Pharma Co Ltd método de bioanálise para detecção de substância fisiologicamente ativa
HUE035017T2 (en) * 2011-11-15 2018-03-28 Quincy Bioscience Llc To reduce neuronal damage caused by Apoaequorin ischemia
GB201700317D0 (en) 2017-01-09 2017-02-22 Calcivis Ltd Detection device
USD1042180S1 (en) 2020-05-28 2024-09-17 Calcivis Limited Dental detection device

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001240855A (ja) * 2000-03-01 2001-09-04 Masashi Sugimoto 生物発光方法及び発光物品
US6800492B2 (en) * 2000-06-01 2004-10-05 Institute Pasteur Chimeric GFP-aequorin as bioluminescent Ca++ reporters at the single cell level
WO2001096361A1 (en) * 2000-06-12 2001-12-20 University Of Maryland Biotechnology Institute Method of controlling the binding of calmyrin to presenilin
US20060229243A1 (en) * 2004-06-21 2006-10-12 Quincy Resource Group, Inc. Aequorin-containing compositions and methods of using same

Also Published As

Publication number Publication date
EP1768691B1 (en) 2013-05-22
CN1997383A (zh) 2007-07-11
AU2005265266B2 (en) 2011-05-12
EP2545934A1 (en) 2013-01-16
KR101213555B1 (ko) 2012-12-18
WO2006010004A2 (en) 2006-01-26
US7671015B2 (en) 2010-03-02
BRPI0512392B1 (pt) 2022-12-13
CA2571542C (en) 2014-08-19
US20080287350A1 (en) 2008-11-20
ES2422173T3 (es) 2013-09-09
PT1768691E (pt) 2013-06-20
EP1768691A2 (en) 2007-04-04
DK1768691T3 (da) 2013-07-01
ZA200610688B (en) 2007-12-27
IL180195A0 (en) 2007-06-03
CN1997383B (zh) 2011-01-05
US20100152117A1 (en) 2010-06-17
US20060229243A1 (en) 2006-10-12
AU2005265266A1 (en) 2006-01-26
PL1768691T3 (pl) 2013-09-30
KR20070070154A (ko) 2007-07-03
IL180195A (en) 2014-03-31
JP2008503581A (ja) 2008-02-07
EP2545934B1 (en) 2014-12-10
EP1768691A4 (en) 2010-08-04
SG153848A1 (en) 2009-07-29
SI1768691T1 (sl) 2013-07-31
CA2571542A1 (en) 2006-01-26
CY1114307T1 (el) 2016-08-31
NZ552274A (en) 2010-06-25
BRPI0512392A (pt) 2008-03-11
JP4971150B2 (ja) 2012-07-11
WO2006010004A3 (en) 2007-03-08
HK1109576A1 (en) 2008-06-13

Similar Documents

Publication Publication Date Title
PL1836169T3 (pl) Kompozycje i sposoby leczenia zaburzeń związanych z proliferacją komórek
IL187382A0 (en) Bicyclic derivatives as modulators of ion channels
GB0515353D0 (en) Food
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
GEP20084550B (en) Substituted morpholine compounds for the treatment of central nervous system disorders
MX2009005455A (es) (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano.
TW200618817A (en) Diffractive colorants for cosmetics
TW200604168A (en) Azaindoles useful as inhibitors of rock and other protein kinases
TW200740803A (en) Heterocyclic derivatives as modulators of ion channels
MX2010003864A (es) Amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
DK2321321T3 (da) Triazolo [4,5-d]pyramidinderivater og anvendelse deraf som purinreceptorantagonister
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
IL193080A0 (en) Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith
MY147767A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200602052A (en) Azaindoles useful as inhibitors of JAK and other protein kinases
MX2010003865A (es) Aril amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
EA201070423A1 (ru) Диарильные соединения оксадиазолов
GB0625648D0 (en) Compounds
GEP20115201B (en) Cinnamoyl-piperazine derivatives and their use as par- i antagonists
ZA200702375B (en) Quinazolines useful as modulators of ion channels
TW200738669A (en) Crystalline forms of N-(benzo[b]thien-3-ylmethyl)-sulfamide
IL205696A0 (en) Heterocyclic derivatives, compositions comprising the same and uses thereof
CY1114307T1 (el) Συνθεσεις που περιεχουν αικουορινη και μεθοδοι που τις χρησιμοποιουν
TW200724140A (en) Hydantoin compounds
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders

Legal Events

Date Code Title Description
FG Grant or registration